| DC11546 |
Azeloprazole sodium |
A novel potent, orally active proton pump inhibitor that irreversibly inhibits H+,K+-ATPase activity with IC50 of 0.28 uM. |
|
| DC21707 |
STX-681 |
A novel potent, orally active, dual-acting aromatase and steroid sulfatase (STS) inhibitor with ICI0 of 0.82 nM and 39 nM, respectively. |
|
| DC11599 |
PF-739 |
A novel potent, pan-AMPK activator with similar potency for all AMPK heterotrimers. |
|
| DC20806 |
BMS-852927 |
A novel potent, partial LXRβ-selective agonist (EC50=9 nM) with 20% LXRα and 88% LXRβ activity compared to a full pan agonist in transactivation assays. |
|
| DC11610 |
AKS1-IN-19 |
A novel potent, selective and orally active ASK1 (MAP3K5) inhibitor with pIC50 of 8.3. |
|
| DC22745 |
SLx-4090
Featured
|
A novel potent, selective and orally active enterocytic microsomal triglyceride transfer protein (MTP) inhibitor that inhibits only MTP localized to enterocytes with IC50 of 6 nM. |
|
| DC11696 |
CM-579 |
A novel potent, selective and reversible dual inhibitor of G9a/DNMTs with IC50 of 16 nM and 32 nM for G9a and DNMT1, respectively. |
|
| DC21667 |
SMM-295 |
A novel potent, selective cannabinoid receptor 2 (CB2) agonist with Ki of 12 nM, >30-fold selectivity over CB1. |
|
| DC20841 |
BRD6989
Featured
|
A novel potent, selective CDK8 inhibitor with IC50 of 0.5 uM against recombinant Cyclin C/CDK8 complex. |
|
| DC11953 |
MU 380 |
A novel potent, selective CHK1 inhibitor 2 nM, >80-fold selectivity over CHK2. |
|
| DC11982 |
CX815 |
A novel potent, selective CXCR2 inhibitor with IC50 of 0.4 nM. |
|
| DC11981 |
CX4152 |
A novel potent, selective CXCR2 inhibitor with IC50 of 7.6 nM. |
|
| DC11827 |
9-ING-41
Featured
|
9-ING-41 is a potent glycogen synthase kinase-3 (GSK-3) inhibitor[1]. 9-ING-41 induces apoptosis and cell cycle arrest at prophase by targeting centrosomes and microtubule-bound GSK-3β. 9-ING-41 has anticancer activity[2]. |
|
| DC11904 |
Olinciguat (IW-1701)
Featured
|
Olinciguat (IW-1701) is an oral guanylate cyclase (sGC) stimulator with concentration-dependent stimulation of sGC in purified rat and human enzyme assays and a whole cell assay. |
|
| DC22940 |
SKF-32802 |
A novel potent, selective hERG potassium channel (Kv11.1) activator that induces a leftward shift in the voltage dependence of activation.. |
|
| DC11854 |
IDX899 |
A novel potent, selective HIV non-nucleoside reverse transcriptase inhibitor (NNRTI) with EC50 of 1, 1.3, 2.8 and 11 nM for WT, K103N, Y181C and K103N/Y181C, respectively. |
|
| DC21703 |
STAT5 inhibitor 17f
Featured
|
A novel potent, selective inhibitor of phosphorylation and transcriptional activity of STAT5, but not STAT3, AKT, or Erk1/2 phosphorylation. |
|
| DC11497 |
IRAK4-IN-28 |
A novel potent, selective IRAK4 inhibitor with IC50 of 51 nM. |
|
| DC22938 |
ICA-027243
Featured
|
A novel potent, selective KCNQ2/Q3 (Kv7.2/Kv7.3) potassium channel opener/activator with EC50 of 0.38 uM.. |
|
| DC22741 |
RY796 R-form |
A novel potent, selective Kv2 channel inhibitor that potently inhibits Kv2.1 and Kv2.2 with IC50 of 0.14 and 0.09 uM, respectively. |
|
| DC22744 |
RY796 racemate |
A novel potent, selective Kv2 channel inhibitor that potently inhibits Kv2.1 and Kv2.2 with IC50 of 0.14 and 0.09 uM, respectively. |
|
| DC12019 |
RY796 |
A novel potent, selective Kv2 channel inhibitor that potently inhibits Kv2.1 and Kv2.2 with IC50 of 0.14 and 0.09 uM, respectively. |
|
| DC11613 |
Mcl1-IN-26 |
A novel potent, selective Mcl-1 inhibitor with IC50 of <3 nM in FRET assays. |
|
| DC22886 |
TASP 0433864 |
A novel potent, selective mGluR2 positive allosteric modulator with EC50 of 199 and 206 nM for human and rat mGlu2, respectively, without exerting agonist activity. |
|
| DC20441 |
MAO-B inhibitor 8f |
A novel potent, selective monoamine oxidase B (MAO-B) inhibitor with IC50 of 29-56 nM. |
|
| DC20467 |
mTOR inhibitor 10 |
A novel potent, selective mTOR inhibitor with biochemical IC50 of 21.7 nM for mTORC1, exhibits cellular potency against mTOR with IC50 of 5 nM. |
|
| DC11985 |
PSTC |
A novel potent, selective Nrf2 activator with pEC50 of 7.7 (inducing of NQO1 specific enzyme activity). |
|
| DC23862 |
MET inhibitor Compound 1 |
A novel potent, selective orally bioavailable MET tyrosine kinase inhibitor with IC50 of <1 nM and 12 nM for unphosphorylated and phosphorylaed MET, respectively. |
|
| DC22977 |
Lu AF-58027 |
A novel potent, selective PDE1 inhibitor with IC50 of 13/45/1.4 nM for PDE1A/B/C, respectively. |
|
| DC11559 |
PDE5-IN-6c |
A novel potent, selective PDE5 inhibitor with IC50 of 0.056 nM for PDE5A1. |
|
